Things are not looking best for Avandia’s chances right now. This morning, the New York Occasions led with the complete story of a damning clinical trial that GlaxoSmithKline sought to cover. In that study, conducted in 1999, GSK found that Avandia had a higher risk of causing heart problems in comparison to its chief rival, Actos. Since then, independent research have called focus on Avandia’s risk and confirmed that it’s riskier. How different will be the two drugs? Pharmacologically speaking, GSK’s Avandia and Takeda’s Actos are quite similar. They belong to a class of drugs referred to as thiazolidinediones, or TZDs, and both can be used only or together with other medicines like metformin, insulin and sulfonylureas.During this period, the patient was withdrawn from the study and was seen at 2 and four weeks again. Methods Spirometry was performed based on the recommendations of the American Thoracic Culture,6 and predicted ideals were obtained based on the criteria of Crapo et al.7 Asthma control was assessed by using the validated Juniper Asthma Control Questionnaire.4 Furthermore, symptoms of coughing, wheezing, upper body tightness, and shortness of breath were evaluated for the seven days before every visit on a 7-point Likert scale.5 Sputum was processed and induced, as described by Pizzichini et al.8 Airway responsiveness to methacholine was measured with the use of the tidal-breathing method described by Cockcroft et al.9 after withholding beta-agonists every day and night.